Health · Pharma & Biotech · 6 hrs ago
FDA grants accelerated approval to GSK lung cancer drug Nelkarmi
The FDA granted US accelerated approval to GSK’s oral lung cancer drug neladalkib, marketed as Nelkarmi.
The drug is for lung cancer.
The approval makes it the second lung cancer drug approved from GSK’s $10.6bn deal to buy Nuvalent.
The deal included two key drug assets, according to the available details.
The approval matters because it gives GSK another lung cancer drug cleared for use in the US.
The available details do not say what happens next.
GSK secured US accelerated approval for an oral lung cancer drug, according to Endpoints News.
The drug is named neladalkib in the article text.
The Financial Times headline describes the approval as the second lung cancer drug from GSK’s $10.6bn Nuvalent deal.
Endpoints News says the drug is one of two assets at the heart of the deal.
- Who
- GSK.
- What
- It won US accelerated approval for an oral lung cancer drug. The articles identify it as the second lung cancer drug from its Nuvalent deal.
- When
- November 17, 2026, the publication date of both articles.
- Where
- The United States.
- Why
- Not stated
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- GSK
- Drug name in article text
- neladalkib
- Approval
- US accelerated approval
- Deal value in FT headline
- $10.6bn
- Deal partner named in FT headline
- Nuvalent
3 sources
What people are saying
GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib